Navigation Links
Survival of head and neck cancer patients is greatly affected by coexisting ailments
Date:11/19/2008

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

This highlights a broader problem with cancer survival statistics, which generally don't take into account the effect of co-existing conditions, or comorbidities, according to Piccirillo.

In a recent study, Piccirillo, director of the Clinical Outcomes Research Office at Washington University School of Medicine and professor of otolaryngology, showed that the risk of death increased up to seven-fold when patients with head and neck cancer developed new or more severe co-existing ailments such as heart problems, diabetes or lung disorders after cancer diagnosis.

The study, published in the October issue of the Archives of Otolaryngology, Head and Neck Surgery, is the first to look at comorbidities in head and neck cancer patients in the period following diagnosis.

"For decades, we have used a cancer staging system based on tumor size, lymph node involvement and whether cancer has spread to other parts of the body when estimating a patient's survival while mostly ignoring how sick patients are from other diseases," Piccirillo says. "In fact, national databases used to estimate cancer survival don't account for comorbidities, and as a result, we don't have very accurate estimates of how long patients are likely to survive their cancers."

Some past studies of head and neck cancer have investigated the effect of comorbidities present at diagnosis, but this study shows that comorbidities grow in severity and frequency in about a third of head and neck cancer patients after their primary cancer treatment is complete.

The outcomes for patients with head an
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
2. Cancer survival rates impact type of Web communities used by patients
3. Intervention program boosts survival in breast cancer patients
4. Psychological interventions associated with breast cancer survival
5. Gender is key factor in determining overall survival of lung cancer patients
6. Tissue analyses indicate survival benefits for some lung cancer patients
7. Advanced lung cancer patients see improved, progression-free survival
8. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
9. Emergency Physicians Reveal Strategies for Improving Sudden Cardiac Arrest Survival Rates in the U.S.
10. Age is not a key factor in cancer survival, but clinical trials exclude older patients
11. Holiday Survival Tips: Mitigate Loneliness by Becoming Your Own Holiday Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2010)... members, to 14 – 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... ... ... ... The Level one Certificate in Health and Safety at Work ...
(Date:3/14/2010)... how hypertension is treated, experts say , , SUNDAY, March ... large five-year study points to fluctuations in blood pressure ... , In the study, British researchers tracked the health ... or calcium channel blocker medication to curb high blood ... percent in terms of swings in blood pressure between ...
(Date:3/14/2010)... Repairing ACL, meniscus at same time is one advance, ... (HealthDay News) -- Repairing a torn knee meniscus at ... is safe and effective in children, a new study ... in the knee joint. The ACL is one of ... included 99 patients, 18 and younger, who had meniscus ...
(Date:3/14/2010)... below currently recommended levels did not significantly ... cardiovascular disease events in adults with type 2 ... cardiovascular disease events, according to new results from ... Diabetes (ACCORD) clinical trial. Similarly, treating multiple blood ... and a statin did not reduce the combined ...
(Date:3/13/2010)... for heart attack, stroke, and inflammation may be ... News) -- The common skin ailment psoriasis may ... other cardiovascular woes, probably through a shared inflammatory ... is mounting evidence for psoriasis as a risk ... Ole Ahlehoff, from Copenhagen University Hospital Gentofte, said ...
Breaking Medicine News(10 mins):Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:More Evidence That Swings in Blood Pressure Raise Stroke Risk 2Health News:Strides Seen in Orthopedic Surgery for Kids 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:Psoriasis Tied to Raised Heart Risk 2
... shut down the beaches in some provinces of Canada ... weeks showed higher than acceptable levels of E.coli organisms. ... Health inspectors closed the beach to swimmers after conducting ... Chenier said the highest results that came back from ...
... ban to entertainment outlets including pubs, nightclubs and karaoke ... diseases. ,The ban will apply to ... already has some of the toughest anti-smoking measures in ... in entertainment outlets is a natural extension of our ...
... Australia's national science agency, says it has developed a ... to 100 years. ,The test, hailed as the ... to a person's DNA and can point to the likelihood ... ,It will also allow doctors to determine an ...
... is expected to replace France as the world's top tourism ... a foreign news agency said China received 22 million foreign ... Taiwan, compared to a mere 300,000 in 1978. ... slow, China has been enjoying double-digit expansion for years. ...
... there is a cure for smelly and pongy feet - special ... the first eco-friendly sock to go on general sale, and experts ... biggest revolutions to take place in the world of clothing. ... are made of the silky material, which is softer, more durable ...
... hoarders have a brain disorder resulting in an all-consuming compulsion ... damages their relationships. ,A sub-type of obsessive-compulsive ... considered by most people to be worthless or useless. Little ... disorders, it is believed in part to have a genetic ...
Other Medicine News:Health News:Beaches Shut Due to High E-coli Level in Water 2Health News:Singapore Extends Smoking Ban to Pubs, Nightclubs 2Health News:A Blood Test Developed in Australia to Repair DNA Damage 2Health News:China to Replace France as World's Top Tourism Destination by 2014 2Health News:Hoarding can Endanger Lives, Says New Study 2
(Date:3/12/2010)... Systems, Inc. (Nasdaq: DCTH ), which is testing its proprietary treatment system for primary and metastatic cancers to the liver, today provided an update on recent corporate developments.   , ... , ... ... ... ...
(Date:3/11/2010)... PARK, Ill., March 11 ... accepted for review the supplemental new drug application ... Lupron ® ... in the palliative treatment of advanced prostate cancer. ... advanced prostate cancer.  Lupron Depot works by suppressing ...
(Date:3/11/2010)... , March 11 Bone ... a US Patent Office Notice of Allowance of ... expressing, secreting, and purifying the NELL-1 sequence of ... line comprises a Chinese hamster ovary (CHO) cell. ... portfolio for musculoskeletal applications of manufacturing and use ...
Breaking Medicine Technology:Delcath Systems Provides Update on Corporate Developments 2Delcath Systems Provides Update on Corporate Developments 3Delcath Systems Provides Update on Corporate Developments 4Delcath Systems Provides Update on Corporate Developments 5Delcath Systems Provides Update on Corporate Developments 6Delcath Systems Provides Update on Corporate Developments 7Delcath Systems Provides Update on Corporate Developments 8Delcath Systems Provides Update on Corporate Developments 9Delcath Systems Provides Update on Corporate Developments 10Delcath Systems Provides Update on Corporate Developments 11Delcath Systems Provides Update on Corporate Developments 12Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3Scripps Research team uncovers chemical basis for extra quality control in protein production 11067 1Scripps Research team uncovers chemical basis for extra quality control in protein production 11067 2Scripps Research team uncovers chemical basis for extra quality control in protein production 11067 3Scripps Research team uncovers chemical basis for extra quality control in protein production 11067 4Vitamin D Linked to Survival in Lymphoma Patients 62986 1Vitamin D Linked to Survival in Lymphoma Patients 62986 2Seasonal Flu Vaccination Rates Still Too Low 62983 1Seasonal Flu Vaccination Rates Still Too Low 62983 2Seasonal Flu Vaccination Rates Still Too Low 62983 3
... NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer announced ... a,significant 61 percent reduction in stroke in patients ... heart disease. In a,separate study, patients who had ... had a significant 53 percent reduction,in the risk ...
... ISIS 301012 coadministered with statins for only five ... levels achieved with,statins alone, with similarly favorable effects ... March 26, 2007,/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced ... ISIS 301012,coadministered with statins presented today at the ...
Other Medicine Technology:Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 2Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 3Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 4Lipitor Provides Unprecedented Cardiovascular Risk Reductions in,Diabetes Patients with Metabolic Syndrome and in Stroke Patients 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: